In a new piece for the New Yorker, Jia Tolentino charts the advent of the Ozempic era—and the complicated forces that have inspired many to use the drug intended to treat Type 2 diabetes for vanity-fueled weight loss. A widespread fixation on Ozempic “seems to have prompted less a public consideration of what it means to be fat than a renewed fixation on being thin,” she writes. |